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Background: Intervertebral disc degeneration (IVDD) is considered a multifactorial dis-
ease that is influenced by both environmental and genetic factors. The last two decades 
of research strongly demonstrate that genetic factors contribute about 75% of the IVDD 
etiology. Recent total genome sequencing studies have shed light on the various sin-
gle-nucleotide polymorphisms (SNPs) that are associated with IVDD.
Aim: This review presents comprehensive and updated information about the diversity 
of genetic factors in the inflammatory, degradative, homeostatic, and structural systems 
involved in the IVDD. An organized collection of information is provided regarding genetic 
polymorphisms that have been identified to influence the risk of developing IVDD. 
Understanding the proteins and signaling systems involved in IVDD can lead to improved 
understanding and targeting of therapeutics.
Materials and methods: An electronic literature search was performed using the 
National Library of Medicine for publications using the keywords genetics of IVDD, lumbar 
disc degeneration, degenerative disc disease, polymorphisms, SNPs, and disc disease. 
The articles were then screened based on inclusion criteria that included topics that 
covered the correlation of SNPs with developing IVDD. Sixty-five articles were identified 
as containing relevant information. Articles were excluded if they investigated lower back 
pain or just disc herniation without an analysis of disc degeneration. This study focuses 
on the chronic degeneration of IVDs.
Results: Various genes were identified to contain SNPs that influenced the risk of devel-
oping IVDD. Among these are genes contributing to structural proteins, such as COL1A1, 
COL9A3, COL9A3, COL11A1, and COL11A2, ACAN, and CHST3. Furthermore, various 
SNPs found in the vitamin-D receptor gene are also associated with IVDD. SNPs related 
to inflammatory cytokine imbalance are associated with IVDD, although some effects 
are limited by sex and certain populations. SNPs in genes that code for extracellular 
matrix-degrading enzymes, such as MMP-1, MMP-2, MMP-3, MMP-9, MMP-14, 
Abbreviations: ADAMTS, a disintegrin and metalloproteinase with thrombospondin motif; AF, annulus fibrosis; ECM, 
extracellular matrix; GDF5, growth differentiation factor 5; IL, interleukin; IVD, intervertebral disc; IVDD, intervertebral 
disc degeneration; MMP, matrix metalloproteinase; MRI, magnetic resonance imaging; NP, nucleus pulposus; SNP, single-
nucleotide polymorphism; VEGF, vascular endothelial growth factor; VNTR, variable nucleotide tandem repeat.
FiGURe 1 | (A) Normal intervertebral disc (IVD) from the sagittal view. (B) Normal IVD from the axial view. (C) Magnified illustration of an IVD. Used with permission 
from Barrow Neurological Institute, Phoenix, AZ, USA.
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iNTRODUCTiON
Over 80% of all people will experience some form of lower back 
pain in their lifetime (1–3). Symptomatic intervertebral disc 
(IVD) degeneration (IVDD) is a common cause of lower back 
pain, yet the etiology and pathophysiology underlying IVDD 
remain poorly understood (4, 5). Although various environ-
mental factors such as smoking, age, gender, and mechanical 
load increase the risk of IVDD, it is hypothesized that up to 74% 
of the etiology of IVDD is due to heritability (2, 6). With lower 
back pain costing over $100 billion/year in the United States, it 
is essential to investigate both the environmental and genetic 
predispositions to IVDD (5).
The normal IVD is composed of two parts: the outer annulus 
fibrosis (AF) region and the central nucleus pulposus (NP) 
(Figure 1). The AF consists of fibroblast-like cells with elongated 
nuclei placed between concentric layers of collagen fibers (3). 
The extracellular matrix (ECM) of the AF can be described 
as a fibrocartilaginous structure consisting of predominantly 
collagen-I fibers (60% of total dry weight), with low proteoglycan 
content (25%) and low water retention (5, 7). Its primary function 
is to provide structural integrity to the disc and hold the contents 
of the NP in the center (3, 5). The NP is a gelatinous structure 
with chondrocyte-like cells that secrete collagen II. Dispersed 
throughout the collagen fibers are an abundance of proteoglycans, 
predominantly aggrecan, which are responsible for facilitating 
water retention (3, 5, 8). The primary function of the NP is to 
create hydrostatic pressure to resist axial compression (5, 7).
Intervertebral disc degeneration seems to be an irreversible 
process that can begin as early as the second decade (5). The first 
molecular change that occurs at the beginning of degeneration 
is a reduced ability of the NP to retain water and consequently 
maintain a significant hydrostatic pressure (7). These changes 
result in decreased disc height and reduced ability of the spine to 
withstand compression. Over time, the collagen fibers and other 
ECM components of both the NP and AF are degraded and 
reduced in quantity (8). Upregulation of degradative systems 
such as apoptosis, inflammation, and matrix metalloproteinases 
(MMPs) further damage the existing (9–13). The past 20 years 
of genomic research has revealed an astounding number of 
genetic polymorphisms of various genes that are correlated 
with increased risk of developing IVDD. Polymorphisms in 
the genes coding for collagen, aggrecan, interleukins (ILs), 
apoptosis factors, vitamin  D receptor (VDR), MMPs, and 
ADAMTS-4, and ADAMTS-5 are also associated with IVDD. Apoptosis-mediating genes, 
such as caspase 9 gene (CASP9), TRAIL, and death receptor 4 (DR4), as well as those 
for growth factors, such as growth differentiation factor 5 and VEGF, are identified to 
have polymorphisms that influence the risk of developing IVDD.
Conclusion: Within the last 10 years, countless new SNPs have been identified in genes 
previously unknown to be associated with IVDD. Furthermore, the last decade has also 
revealed new SNPs identified in genes already known to be involved with increased risk 
of developing IVDD. Improved understanding of the numerous genetic variants behind 
various pathophysiological elements of IVDD could help advance personalized care and 
pharmacotherapeutic strategies for patients suffering from IVDD in the future.
Keywords: back pain, biomarker, degeneration, disc, gene expression, herniation, personalized care, single-
nucleotide polymorphism
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other critical proteins involved in IVDD are examined in this 
paper. Although previous reviews have documented the various 
single-nucleotide polymorphisms (SNPs) that are associated 
with IVDD, we aim to provide an up-to-date and comprehensive 
review of the subject (5, 7, 8).
With an improved understanding of the genetic variants 
associated with IVDD, we hope to help advance personal-
ized care and pharmaceutical therapies for patients suffering 
from IVDD. Across various medical specialties, genome 
sequencing has begun to play a significant role in improving 
the care provided to patients (14). Human genome analysis 
allows physicians to obtain a deeper understanding of the 
pathophysiology of diseases to provide improved risk and 
prognostic assessments to patients. Furthermore, information 
regarding genetic variants provides insight into therapeutic 
options as physicians are better able to target the underlying 
disease-causing mechanisms (15). Throughout this paper, we 
will explore the complexity and diversity of the molecular and 
genetic factors involved in IVDD. Genetic variants from various 
molecular pathways are investigated including inflammatory, 
degradative, homeostatic, and structural systems. Clinical 
use of genome analysis allows physicians to pinpoint which 
systems and particular pathways are involved with the patient’s 
unique case of IVDD and subsequently provide personalized 
and improved health care.
MeTHODS
An electronic literature search was performed using the National 
Library of Medicine for publications using these keywords: 
genetics of IVDD, lumbar disc degeneration, degenerative disc 
disease, polymorphisms, SNPs, and disc disease. The articles 
were then screened based on inclusion criteria that included top-
ics that covered the correlation of SNPs with developing IVDD. 
Furthermore, articles containing supporting information regard-
ing the treatment and diagnosis of IVDD were included. Sixty-five 
total articles were identified as containing relevant information. 
Articles were excluded if they investigated lower back pain or disc 
herniation without an analysis of disc degeneration or study of 
correlation with SNPs. This investigation focuses on the chronic 
degeneration of IVDs and the genetic factors that influence its 
development.
TReATMeNT FOR ivDD
Diagnosis of IVDD requires a careful history, physical exami-
nation, and, most importantly for the experimental studies 
included in this review, magnetic resonance imaging (MRI) of 
the spine. The majority of studies that were included in this 
literature review used axial and/or sagittal T2-weighted MRIs to 
evaluate the lumbar spine of the patients (Figure 2). Once the 
patient has been accurately diagnosed with disc degeneration, 
limited approved therapeutics are available to abate the progres-
sion of the degeneration. Therapy to combat IVDD and the 
associated degeneration and pain is highly complex, and it can 
be difficult to predict its effectiveness. Recently, researchers have 
found success utilizing targeted molecular and gene therapies in 
an attempt to mitigate degradation and even promote anabolic 
processes. Injection of recombinant human bone morphogenetic 
protein 7 (BMP-7, also known as osteogenic protein 1, OP-1) 
has been successful in a rabbit model (16). BMP-7 injection 
restored the disc height and biomechanical properties of the 
damaged disc. Other growth factors such as rhGDF-5 have also 
shown great promise (17). In that study, a single injection was 
shown to increase disc height. Furthermore, rhGDF-5 injection 
has been shown to reduce the expression of ADAMTS-4 and 
ADAMTS-5 proteins for which, the genes have been identified 
to contain SNPs associated with altered risk of developing IVDD 
(18). This serves as an excellent example of the intersection of 
providing targeted therapy and gene analysis of patients with 
IVDD. RhGDF-5 injections may serve as the most effective 
therapy in a patient who has been screened for having high-risk 
IVDD due to SNPs in their ADAMTS-4 and -5 genes (18). 
Furthermore, injection of other molecules, such as TGF-β1 
and BMP-2, has been shown to inhibit MMP-1 expression 
and increase expression of aggrecan protein. Genes for both 
MMP-1 and aggrecan protein are known to contain SNPs that 
predispose patients to develop IVDD (19). Combining the 
specific effects of these anabolic therapies with an understand-
ing of the individualized molecular profile of each patient may 
yield a highly effective treatment. Therefore, it is essential that 
research efforts continue to progress in both targeted therapies 
and gene analysis of IVDD.
The most effective experimental approach in the treatment of 
IVDD is the use of viral vectors in gene therapy. In vitro bovine 
experimentation with the delivery of sex-determining region Y 
box 9 (SOX9) and BMP7 through an adenovirus vector revealed 
increased expression of type II collagen and an increase in disc 
height (21). Another experiment showed that cells virally trans-
duced with Ad-BMP-4 and -14 displayed an increase in collagen 
deposition, whereas cells transduced with Ad-BMP-2 and -7 
displayed an increase in proteoglycan accumulation (19). The 
consistently positive results obtained from these experiments 
suggest a largely uncharted frontier exists in the use of personal-
ized medicine for IVDD.
GRADiNG ivDD
Physicians utilize various grading systems to assist in diagnos-
ing and measuring the severity of IVDD and to determine the 
most standardized and objective classification of disc degenera-
tion. A popular and widely accepted scale is the Pfirrmann 
grading system. The system includes grades 1–5, where grade 
1 signifies a normal disc with homogenous hyperintensity 
on MRI, and grade 5 signifies a collapsed disc space with 
a hypointense signal (Figure  2) (22). A common critique of 
the system is its subjectivity. It is often modified or combined 
with other grading systems such as Modic changes to create 
an objective, reproducible system (23). Some physicians and 
research groups opt to develop their own grading system, while 
others utilize classification systems such the one developed 
by Schneiderman et  al. (13, 24–26). Once a patient’s disc 
degeneration is objectively graded, a standard of care can be 
established.
FiGURe 2 | MRis of intervertebral disc disease in patients with total Pfirrmann scores of (A) 24, (B) 18, and (C) 13 and the assessed score for each 
lumbar disc. The Pfirrmann grading scale for disc degeneration classifies discs into 5 grades according to the amount of degeneration. Grade 1 corresponds to a 
hyperintense healthy disc, while grade 5 corresponds to a hypointense severely degenerated disc. The figure contains a point system corresponding to each 
intervertebral disc from L1 to S1. Five points were given for a grade 1 score, four points for a grade 2, three for a grade 3, two for a grade 4, and one for a grade 5. 
The highest possible total score is 25; the lowest possible score is 5. Used with permission from Toktas et al. (20).
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GeNe POLYMORPHiSMS ASSOCiATeD 
wiTH ivDD
Table 1 (1, 4, 11–13, 20, 24, 25, 27–57) presents comprehensive 
information on the research studies that have investigated 
genes with SNPs associated with IVDD and their protein 
products. Table  2 (1, 4, 11–13, 20, 24, 25, 27–58) summa-
rizes the protein systems associated with such changes in the 
respective genes.
Collagens
Collagen is the most abundant protein found in the human 
body, with 28 different types. Throughout the body, the various 
collagen types are found in the ECM and have different structural 
support roles. Structurally, collagen fibers are composed of three 
polypeptide chains, referred to as α chains, that form one or 
more triple-helixes along their rod-shaped structure (59). When 
referring to the gene that produces a specific collagen type, the 
gene name and subunit name are given (e.g., collagen type IX 
alpha 2, COL9A2). The collagen types of interest to us are the 
ones found within IVDs: collagen I, II, IX, and XI.
The AF consists primarily of collagen I, a fibril-forming 
collagen. Fibrillar collagens – I, II, and III – are essential in 
defining the molecular and mechanical properties of a particular 
tissue (59). In the AF, collagen I is responsible for maintaining 
the tensile strength to withstand spinal compression, hydrostatic 
pressure, and keeping the NP contained. Collagen II is the 
primary collagen of the NP and is found as a loosely connected 
network (3). Various minor collagens such as collagen IX play 
an important supporting role in forming cross-links between dif-
ferent types of collagen, increasing structural strength. Collagen 
XI, although found in small amounts, is important in structural 
support of collagen II as well as forming connections between 
proteoglycans and collagen (5, 8). Considering the integral role 
of collagen in maintaining the structural integrity of the IVD, 
genetic polymorphisms affecting the function or abundance of 
collagen can predispose a patient to IVDD.
Collagen I
Collagen I, although found in both the NP and AF, is much more 
abundant within the AF of the IVD. Collagen I is made up of a 
helix consisting of two α1 chains, encoded by the collagen type I 
alpha 1 gene, COL1A1, and one α2 chain encoded by the collagen 
type I alpha 2 gene COL1A2 (7). COL1A1 contains a particular 
polymorphism that may be involved with increased risk of IVDD. 
Three noteworthy studies have established an association between 
the COL1A1 Sp1-binding site SNP and IVDD (20, 27, 28). This 
particular SNP is a G to T substitution at position +1245, which is 
found within the first intron of the COL1A1 gene (60). The change 
in nucleotides reportedly increases levels of COL1A1 messenger 
RNA expression and subsequently COL1A1 protein expression 
(27). Investigators have hypothesized that the SNP leads to dis-
equilibrium between COL1A1 and COL1A2 protein expression 
leading to instability of the collagen fibers (27, 28). Pluijm et al. 
examined 966 elderly (>65 years) Dutch individuals and reported 
that patients with the TT genotype had a 3.6-fold increased sus-
ceptibility to IVDD than patients with the GT or GG genotypes 
(27). The following year, Tilkeridis et al. examined the frequency 
of the Sp1-binding site polymorphism in 24 young Greek military 
recruits (28). The study reported that 33.3% of the patients with 
IVDD had the TT genotype while none of the control subjects 
did. Furthermore, the study indicated that 66.7% of the IVDD 
patients had the GT genotype while only 41.7% of the controls 
did. More recently, a 2015 study by Toktas et al. found that patients 
homozygous for the risk allele T had a significantly lower average 
Pfirrmann score (17.63) than patients without the allele (average 
score, 21.88) (20). They found a similar relationship between 
patients heterozygous for the allele compared with control 
patients. This study suggests that the COL1A1 Sp1 polymorphism 
may not only be associated with an increased risk of developing 
IVDD but also associated with more severe forms of degeneration.
Collagen IX
Collagen IX is composed of three unique polypeptides, such 
as α1, α2, and α3, which are encoded by genes collagen type 9 
TABLe 1 | Summary of research studies on single-nucleotide polymorphisms (SNPs) associated with intervertebral disc degeneration (ivDD).
Reference Protein SNP Study population Results
Pluijm et al. 
(27)
Collagen I COL1A1 Sp1 966 Elderly Dutch subjects (>65 years old) TT genotype odds ratio (OR) = 3.6 compared with 
GT or GG
Tilkeridis 
et al. (28)
Collagen I COL1A1 Sp1 24 Greek military recruits (mean age 29 years old), 
12 controls (mean age 25 years old)
TT genotype found in 33.3% of patients with IVDD 
and 0% of controls; GT genotype found in 66.7% 
of patients with IVDD and 41.7% of controls
Toktas et al. 
(20)
Collagen I COL1A1 Sp1 75 Southern European men with IVDD, 25 
controls (35–45 years old)
T allele associated with more severe IVDD based 
on Pfirrmann scores
Annunen 
et al. (29)
Collagen IX COL9A2 Trp2 157 Finnish subjects (19–78 years old) with sciatic 
pain, 174 controls
Trp2 allele OR = 4.5 compared with patients 
without allele
Kales et al. 
(30)
Collagen IX COL9A2 Trp2 105 Greek patients with IVDD, 102 controls 
(<60 years old)
No association between Trp2 and IVDD
Toktas et al. 
(20)
Collagen IX COL9A2 75 Southern European men with IVDD, 25 
controls (35–45 years old)
Did not find association between Trp2 and IVDD
Zhang et al. 
(31)
Collagen IX COL9A2 
rs12077871, 
rs12722877, 
rs7533552
Meta-analysis with 1522 lumbar disc disease 
(LDD) cases, 1646 controls
No association between the SNPs and IVDD
Paassilta 
et al. (32)
Collagen IX COL9A3 Trp3 171 Finnish patients with sciatic pain, 321 controls 
(mean age 45 years old)
Trp3 allele OR = 2.7 for developing IVDD
Solovieva 
et al. (33)
Collagen IX COL9A3 Trp3 135 Finnish male patients (40–45 years old) Trp3 allele OR = 7.0 for developing dark nucleus 
pulposus; OR = 8.0 for degeneration of spine in 
absence of IL-1 βT3954 SNP allele
Toktas et al. 
(20)
Collagen IX COL9A3 Trp3 75 Southern European men with IVDD, 25 
controls (35–45 years old)
Trp3 allele associated with more severe 
degeneration based on Pfirrmann scores
Solovieva 
et al. (33)
Collagen XI COL11A2 G to A 
SNP within intron 9
135 Finnish male patients (40–45 years old) Risk allele OR = 2.1 for increased risk of disc 
bulges
Videman 
et al. (4)
Collagen XI rs2072915, 
rs9277933, 
rs2076311, 
rs1337185, 
rs1463035
588 Finnish male twins (35–70 years old) Some SNPs were significantly associated with 
reduced disc signal on MRI while others were 
associated with disc bulging
Rajasekaran 
et al. (34)
Collagen XI rs1337185 308 Indian male patients with mild Total Disc 
Degenerative Score (mean age 29.6 years old), 
387 Indian male patients with severe TDDS (mean 
age 31.7 years old)
SNP rs1337185 OR = 1.55 for developing IVDD
Virtanen 
et al. (35)
Interleukin-1a -889C/T 150 Finnish men (38–56 years old), 61 control 
subjects
TT genotype OR = 7.87 for developing IVDD 
compared with patients with CC genotype
Eskola 
et al. (36)
Interleukin-1a -889C/T 96 Danish adolescents with IVDD, 57 controls 
(mean age 13.1 years old at the beginning of the 
study)
In girls, the T-allele OR = 2.82 for disc 
degeneration
Noponen-
Hietala et al. 
(37)
Interleukin-6 T15A within exon 5 155 Finnish subjects (17–78 years old), 179 
controls (20–69 years old)
AA or AT genotypes OR = 4.4 for IVDD
Eskola 
et al. (13)
Interleukin-6 rs1800796, 572G/C 66 Children with LDD, 154 controls; total 352 
children studied (mean age 13.1 years old at the 
beginning of the study)
C allele OR = 6.71 for IVDD in females
Eskola 
et al. (36)
Interleukin-6 rs1800797(Risk 
allele G), rs1800795 
(Risk allele G)
96 Danish adolescents with IVDD, 57 controls 
(mean age 13.1 years old at the beginning of the 
study)
GA genotype of rs1800797 OR = 0.27 for IVDD; 
GC genotype of rs1800895 OR = 0.26 for IVDD 
in males
Dong 
et al. (38)
Matrix 
metalloproteinase 
(MMP)-2
-1306C/T 162 Chinese young adults with IVDD (mean 
age 25.4 years old), 318 controls (mean age 
24.1 years old)
CC genotype OR = 3.08 for developing IVDD; CC 
genotype also associated with more severe forms 
of IVDD
Zhang 
et al. (39)
MMP-2 -735C/T 1008 Chinese Han patients with LDD (mean 
age 50.12 years old), 906 controls (mean age 
49.54 years old)
Patients with TT or CT genotype OR = 0.413 
for developing IVDD. CC genotype OR = 2.5 for 
developing IVDD compared with TT
Sun 
et al. (11)
MMP-9 -1562C/T 408 Northern Chinese young adults with IVDD 
(18–21 years old), 451 controls (16–30 years old)
TT and CT genotypes OR = 2.14 for developing 
IVDD
(Continued)
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Reference Protein SNP Study population Results
Takahashi 
et al. (40)
MMP-3 5A Variant 54 Young Japanese (18–28 years old) and 49 
elderly (64–94 years old) patients
5A/6A and 5A/5A genotypes associated with 
increased risk of IVDD in elderly
Yuan et al. 
(12)
MMP-3 5A Variant 178 Chinese patients with IVDD (mean age 
48.5 years old), 284 controls (mean age 
40.6 years old)
5A allele OR = 2.5 for developing IVDD; 5A allele 
also associated with more severe forms of IVDD
Zhang 
et al. (41)
MMP-14 -378T/C 908 Chinese Han IVDD patients with IVDD (mean 
age 51.12 years old), 906 controls (mean age 
51.54 years old)
TT genotype OR = 1.59 for developing IVDD 
compared with CC genotype
Liu et al. (42) A disintegrin and 
metalloproteinase 
with thrombospondin 
motif (ADAMTS)-4
rs4233367: 1877C/T 482 Chinese Han patients (mean age 42.6 years 
old), 496 controls (mean age 41.4 years old)
TT genotype OR = 0.21 for developing IVDD 
compared with CC genotype
Rajasekaran 
et al. (34)
ADAMTS-5 rs162509 308 Indian male patients with mild Total Disc 
Degenerative Score (mean age 29.6 years old), 
387 Indian male patients with severe TDDS (mean 
age 31.7 years old)
Risk allele OR = 1.281 for developing IVDD
Kawaguchi 
et al. (43)
Aggrecan VNTR 64 Young women (20–29 years old), 32 cases, 32 
controls
Patients with 18 or 21 repeats were at greater 
risk of developing IVDD than patients with longer 
alleles
Eser 
et al. (24)
Aggrecan VNTR 150 Turkish young adults with IVDD, 150 controls 
(20–30 years old)
A13–26 length alleles associated with higher risk 
of IVDD than longer alleles
Xu et al. (44) Aggrecan VNTR Meta-analysis Repeats of <25 OR = 1.85 for developing IVDD
Gu et al. (45) Aggrecan VNTR Meta-analysis with 965 cases and 982 controls A13–25 repeats OR = 1.52 for developing IVDD. 
In Asian patients specifically, OR = 1.65
Solovieva 
et al. (46)
Aggrecan VNTR 132 Finnish middle-aged men (41–46 years old) A26 allele associated with increased risk of dark 
NP on MRI. A26/A26 genotype OR = 2.77 for 
dark NP compared with longer or shorter alleles
Song 
et al. (47)
Carbohydrate 
sulfotransferase 3 
(CHST3)
rs4148941 4043 Patients with LDD; 28,599 controls AA or AC genotype OR = 1.49 for developing 
IVDD
Videman 
et al. (48)
Vitamin D receptor FokI 85 Pairs of Finnish twins (35–69 years old) Ff and ff genotypes associated with reduced disc 
signal intensity on MRI
Eser et al. 
(24)
Vitamin D receptor FokI 150 Turkish young adults with IVDD, 150 controls 
(20–30 years old)
ff Genotype associated with more severe grades 
of IVDD (grades III, IV)
Vieira 
et al. (49)
Vitamin D receptor FokI 121 Brazilian patients with IVDD (mean male 
age 46.0 years old, female 45.2 years old), 131 
Brazilian population controls (mean male age 
33.8 years old, female 33.9 years old)
T allele OR = 1.58 for developing IVDD. Ff and 
ff genotypes OR = 1.742 for developing IVDD in 
Hispanics; OR = 1.293 in Asians
Videman 
et al. (48)
Vitamin D receptor TaqI 85 Pairs of Finnish twins (35–69 years old) tt Genotype associated with reduced disc signal 
intensity on MRI
Kawaguchi 
et al. (50)
Vitamin D receptor TaqI 205 Japanese young adults (mean age 22) Tt genotype associated with multilevel disc 
degeneration
Eser 
et al. (24)
Vitamin D receptor TaqI 150 Turkish young adults with IVDD, 150 controls 
(20–30 years old)
TT genotype associated with milder forms of IVDD 
compared with tt genotype
Toktas 
et al. (20)
Vitamin D receptor TaqI 75 Southern European men with IVDD, 25 
controls (35–45 years old)
tt Genotype associated with more severe forms of 
IVDD based on Pfirrmann scores
Yuan 
et al. (12)
Vitamin D receptor ApaI 178 Chinese patients with IVDD (mean age 
48.5 years old), 284 controls (mean age 
40.6 years old)
Risk allele OR = 1.70 for developing IVDD
Zawilla 
et al. (51)
Vitamin D receptor ApaI 84 Egyptian patients with IVDD (mean age 
44.2 years old) and 60 controls (mean age 
43.3 years old)
Mutant T allele OR = 3.1 for developing IVDD; 
T allele also associated with more severe forms 
of IVDD
Guo et al. (1) Caspase-9 rs4645978: 
-1262A/G
154 Patients with LDD (20–65 years old), 216 
controls (20–65 years old)
GG genotype of rs4645978 OR = 2.76 for 
developing IVDD compared with AA genotype
Mu et al. (52) Caspase-9 rs4645978: 
-1262A/G
892 Chinese male soldiers: 305 cases (mean 
age 21.94 years old), 587 controls (mean age 
22.09 years old)
G allele OR = 2.059 for developing IVDD
TABLe 1 | Continued
(Continued)
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TABLe 2 | Summary of proteins influenced by changes due to SNPs in 
their respective genes.
System Protein
Structural Collagen I (20, 27, 28)
Collagen IX (20, 29–33)
Collagen XI (4, 33, 34)
Aggrecan (24, 43–46)
Structural support Carbohydrate sulfotransferase (47)
Vitamin D receptor (12, 20, 48–51)
Cytokines Interleukin-1a (35, 36)
Interleukin-6 (13, 36, 37)
Extracellular matrix-degrading enzymes Matrix metalloproteinase (MMP)-1 (58)
MMP-2 (38, 39)
MMP-3 (12, 40)
MMP-9 (11)
MMP-14 (41)
A disintegrin and metalloproteinase with 
thrombospondin motif (ADAMTS)-4 (42)
ADAMTS-5 (34)
Apoptotic factors TNF (tumor necrosis factor)-related 
apoptosis-inducing ligand (TRAIL) (53)
Death receptor 4 (25)
Caspase-9 (1, 52)
Parkin (56)
Growth factors Growth differentiation factor 5 (52, 54)
Vascular endothelial growth factor (55)
Pain mediators Cyclooxygenase 2 (34)
Catechol-O-methyltransferase (57)
Reference Protein SNP Study population Results
Xu et al. (53) TNF (tumor necrosis 
factor)-related 
apoptosis-inducing 
ligand (TRAIL)
1525A/G, 1595T/C 100 Chinese patients with IVDD (31–81 years old), 
100 controls (34–70 years old)
GG genotype of 1525A/G and CC genotype of 
1595T/C associated with increased risk of IVDD 
and more severe forms of IVDD (grade IV)
Tan et al. (25) Death receptor 4 
(DR4)
rs4871857: C626G 296 Chinese Han patients with IVDD (mean 
age 48.42 years old), 208 controls (mean age 
47.90 years old)
Mutant G allele OR = 1.958 for developing IVDD; 
GG and GC genotypes associated with more 
severe forms of IVDD
Williams 
et al. (54)
Growth differentiation 
factor 5 (GDF5)
rs143383 Meta-analysis including 5295 Northern European 
women (19–90 years old)
T allele OR = 1.72 for disc space narrowing and 
osteophyte production
Mu et al. (52) Growth differentiation 
factor 5 (GDF5)
rs143383 892 Chinese male soldiers: 305 cases (mean 
age 21.94 years old), 587 controls (mean age 
22.09 years old)
T allele OR = 2.115 for low back pain
Han et al. 
(55)
Vascular endothelial 
growth factor (VEGF)
-2578C/A, -634CC 102 Young Koreans with IVDD (mean age 
23.6 years old), 139 controls (mean age 
23.4 years old)
SNPs -2568CA or AA genotype, -634CC 
genotype OR = 21 for developing IVDD
Williams 
et al. (56)
Parkin rs926849 Meta-analysis of 4600 Northern Europeans 
(18–85 years old)
Mutant C allele associated with reduced risk of 
IVDD
Rajasekaran 
et al. (34)
Cyclooxygenase 2 
(COX2)
rs5277, rs5275 308 Indian male patients with mild Total Disc 
Degenerative Score (TDDS, mean 29.6 years old), 
387 Indian male patients with severe TDDS (mean 
age 31.7 years old)
SNPs rs5277 and rs5275 significantly associated 
with IVDD
Gruber et al. 
(57)
Catechol-O-
methyltransferase 
(COMT)
rs165656, rs4633, 
rs2095019, 
rs4708592
40 Patients with disc degeneration SNPs rs165656, rs4633, rs2095019, and 
rs4708592 significantly associated with IVDD
TABLe 1 | Continued
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alpha 1 (COL9A1), collagen type 9 alpha 2 (COL9A2), and col-
lagen type  9 alpha 3 (COL9A3), respectively (20). Collagen IX 
is thought to play a significant role in connecting various types 
of collagens together, particularly collagen II (8, 59). Various 
studies have found SNPs located on either COL9A2 or COL9A3 
that may be associated with increased risk of IVDD.
Annunen et al. examined 157 unrelated Finnish subjects with 
IVDD-induced sciatica (29). The study characterized a COL9A2 
polymorphism named Trp2, which caused a substitution of Gln 
or Arg for Trp in the collagen molecule. This substitution is par-
ticularly interesting because there are no naturally occurring Trp 
residues in collagen because the COL9 gene does not encode for 
the amino acid Trp. The statistical analysis showed that patients 
with the allele coding for Trp were at a 4.5-fold increased risk 
of developing IVDD than those without the allele (29). Their 
population analysis found that 6 of the 157 individuals with 
IVDD had the Trp allele while none of the 174 controls did. A 
few other investigators have attempted to establish a connection 
between the Trp2 allele and IVDD but failed. For instance, Toktas 
et al. (20), Kales et al. (30), and Zhang et al. (31) did not find a 
correlation between COL9A2 polymorphisms and IVDD.
A common SNP that has been studied in COL9A3 is Trp3. 
This SNP is similar to the one found in COL9A2; it is an Arg103 
to Trp substitution. Paassilta et al. studied the occurrence of the 
Trp3 allele in 171 Finnish subjects (32). The statistical analysis 
showed that patients who had a copy of the Trp3 allele were at 
a 2.7-fold increased risk of developing IVDD compared with 
patients who did not have the allele. Evidence for the association 
between the Trp3 allele and IVDD grew with a 2006 study by 
Solovieva et  al. (33). They examined 135 middle-aged Finnish 
men and found that patients who carried the Trp3 risk allele 
in the absence of the IL-1 βT3954 SNP allele were at a 7.0-fold 
increased risk of a dark NP on MRI. These men had an overall 
8Martirosyan et al. Genetics of Degenerated Discs
Frontiers in Surgery | www.frontiersin.org November 2016 | Volume 3 | Article 59
8.0-fold increased risk of degenerative changes in the spine. 
Although this study qualified the association between Trp3 
and IVDD as dependent on the absence of the IL-1 βT3954 SNP 
allele, it nonetheless established a connection between the two 
(33). More recently, a 2015 study by Toktas et  al. established a 
connection between the Trp3 allele and increased severity of 
disc degeneration (20). The study showed that of the five cases 
with Trp3 alleles, the heterozygous patients with the allele had 
a significantly lower average Pfirrmann score (19.40) compared 
with the wild-type patients without the allele (average score, 
21.07). This finding suggests that not only is the Trp3 allele 
associated with an increased risk of developing IVDD but also 
associated with more severe forms of degeneration.
Collagen XI
Collagen XI has a similar structure to collagen IX in that it is a 
heterotrimer. The three chains, such as α1, α2, and α3, are coded 
by collagen type XI alpha 1 (COL11A1), collagen type XI alpha 2 
(COL11A2), and collagen type II alpha 1 (COL2A1), respectively 
(5). Collagen XI is found in both the AF and NP of IVDs and 
has an important role in connections between the different col-
lagen molecules, particularly collagen II, as well as connections 
between proteoglycans and collagen (5, 8).
Solovieva et  al. showed a relationship between a G to A 
substitution SNP within intron 9 of COL11A2 and disc bulging 
(33). Patients who were carriers of the SNP allele had a 2.1-fold 
increased risk of disc bulging compared with patients who did 
not have the allele. The study also noted a 1.6-fold increased 
risk of signs of disc degeneration, but the SD was too large to be 
statistically significant. Nonetheless, it is worth noting that the 
G to An SNP of COL11A2 was related to change associated with 
disc degeneration. A 2009 study by Videman et al. documented 
five different polymorphisms in collagen XI genes that were 
significantly associated with signs of disc degeneration such as 
reduced disc signal and disc bulging (4). This particular large-
scale study enrolled 588 Finnish male twins ranging from 35 to 
70 years of age. The rs2072915, rs9277933, and rs2076311 SNPs of 
COL11A2 were significantly associated with reduced disc signal 
on MRI, whereas the rs1337185 and rs1463035 polymorphisms of 
COL11A1 were significantly associated with increased risk of disc 
bulging. A 2015 study by Rajasekaran et al. supported these find-
ings (34). The study revealed the rs1337185 SNP of COL11A1 was 
associated with a 1.55-fold increased risk of developing IVDD. 
Research suggests that SNPs in both COL11A2 and COL11A1 
could predispose an individual to an increased risk of developing 
IVDD.
Cytokines
Cytokines, such as IL-6, IL-1a, IL-1b, and tumor necrosis factor 
(TNF)-α, are some of the key pro-inflammatory mediators that are 
found and released at sites of tissue injury. IL-1 is naturally found 
within the IVD and is responsible for indirectly degrading ECM 
components through the production of degradative enzymes, 
upregulation of other cytokines, and preventing the produc-
tion of ECM components (5). IL-1 has three different subtypes: 
IL-1a, IL-1b, and IL-1RN. The alpha and beta subtypes are pro-
inflammatory, whereas IL-1RN is anti-inflammatory (7). Within 
the disc, a delicate homeostasis between the pro-inflammatory 
and anti-inflammatory subtypes exists that is easily disturbed by 
trauma to the spine and genetic polymorphisms.
A common SNP of interleukin 1 alpha (IL1A) was signifi-
cantly associated with IVDD in a 2007 study by Virtanen et al. 
who examined 150 Finnish men (35). The SNP is an -889C/T 
substitution where the T allele is the risk allele. Patients in the 
study with the TT genotype were at a 7.87-fold increased risk of 
developing IVDD compared with patients with the CC genotype. 
These findings were supported by a 2012 study by Eskola et al. of 
Danish adolescents (36). The study found a 2.82-fold increased 
risk of developing IVDD among girls who were carriers of the T 
allele compared with the controls. The study also described the 
polymorphism as increasing IL-1a expression, and thus further-
ing its function as a cartilage destroyer (36). These two studies, 
along with a few others, established the -889C/T SNP of IL1A as 
a genetic risk factor for IVDD (7, 35, 36).
Interleukin-6 is an important mediator of inflammation and 
having involvement with lumbar disc herniation (36). Despite 
this information, the exact role of IL-6 in disc degeneration is not 
fully known (5). Noponen-Hietala et al. documented an SNP in 
the interleukin 6 gene (IL6) that was significantly associated with 
IVDD (37). A 15T/A substitution was located within exon 5 of 
IL6. Statistical analysis showed that patients with the AA or AT 
genotypes were at a 4.4-fold increased risk of IVDD than patients 
with the TT genotype. The study documented that the 15T/A 
SNP results in an exon 5 amino acid substitution that replaces Asp 
with Glu. The researchers hypothesized that this polymorphism 
led to disequilibrium of the pro-inflammatory cytokines and, 
therefore, accelerated inflammation (37).
Another SNP associated with IL6 was described in a 2010 study 
by Eskola et al. (13). They identified SNP rs1800796, a 572G/C 
substitution, which was significantly associated with IVDD in 
Danish girls. The study found that female patients carrying the 
C allele were at a 6.71-fold increased risk of developing IVDD 
than those without the allele. This study did not find the same 
association in Danish boys (13). However, a 2012 study by Eskola 
et al. described two different SNPs of IL6 that were found only 
in adolescent boys: rs1800797 and rs1800795. The G/A genotype 
(risk allele, G) of SNP rs1800797 was associated with a 0.27-fold 
decreased risk of developing IVDD, whereas the G/C genotype 
(risk allele, G) of SNP rs1800795 was associated with a 0.26-fold 
decreased risk of IVDD. Both polymorphisms were protective and 
potentially reduced the inflammatory tone of IL6 (36). Overall, 
the research on IL6 suggests that various polymorphisms may 
influence a patient’s genetic risk of IVDD; however, this effect 
may be limited to certain genders or populations.
Matrix-Degrading enzymes
Several types of matrix-degrading enzymes exist within the 
ECM of IVDs. Two of the major types of matrix-degrading 
enzymes that are involved in IVD degradation are MMPs and 
“a disintegrin and metalloproteinase with thrombospondin 
motif ” (ADAMTS). The homeostasis of ongoing ECM turnover 
is managed by the balance between MMPs and tissue inhibitors 
of metalloproteinases (12). Various MMPs are responsible for 
degrading different substances. For example, collagen I, II, and III 
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are primarily degraded by MMP-1, -8, and -13 – the collagenases, 
whereas denatured collagen is the target of MMP-2 and MMP-9 
(59). It is important to remember that increased expression of 
MMPs leads to accelerated destruction of the ECM. ADAMTS are 
also referred to as aggrecanases because their primary function 
within the IVDs is to digest aggrecan (34). Similarly, an increase 
in expression of ADAMTS results in accelerated IVDD.
Matrix Metalloproteinase
Song et al. examined 691 southern Chinese people between the 
ages of 18 and 55 years and found an SNP at position -1607 in 
the promoter of the matrix metalloproteinase 1 gene (MMP-1) 
(58). The SNP was significantly associated with IVDD, and of 
the two alleles, D and G, the D allele was the risk allele. The 
statistical analysis revealed that patients carrying the D allele had 
a 1.41-fold increased risk of IVDD compared with those without 
the allele. Further analysis showed an even stronger connection 
in patients over the age of 40 years. In patients over the age of 
40 years carrying the D allele, there was a 1.445-fold increased 
risk of developing IVDD. This study was particularly interesting 
because previous studies have shown the G allele of the -1607 
SNP as increasing MMP-1 expression. The researchers hypoth-
esized that expression of the D allele might lead to disequilibrium 
between the MMPs, and thus, greater degradation of the AF and 
NP (58).
MMP-2, one of the two gelatinases, tends to target denatured 
collagen as its substrate (59). Dong et al. found that the -1306C/T 
polymorphism of the MMP2 gene was a genetic risk factor for 
IVDD (38). The study examined 162 Chinese young adults with 
disc degeneration. The statistical analysis demonstrated that 
patients with the CC genotype had a 3.08-fold increased risk of 
developing IVDD than those with at least one T allele (CT or TT). 
The study also found that the CC genotype was associated with 
more severe forms of IVDD than the CT and TT genotypes. This 
study was exceptionally interesting because the SNP is a C to T 
substitution, where the T allele is the risk allele, and the C allele 
is the wild-type. The T allele reduces Sp1 transcription factor 
binding to the gene and thus reduces overall transcription. The 
polymorphism that leads to increased protein production is the 
most likely one associated with an increased genetic risk of IVDD; 
in this case, it happened to be the wild-type C allele (38). A later 
study in 2013 by Zhang et al. revealed a similar phenomenon in 
the -735C/T polymorphism of MMP2 (39). The study found that 
patients with the TT or CT genotypes had a 0.413-fold reduced 
risk of developing IVDD, whereas patients carrying the CC 
genotype were at nearly a 2.5-fold increased risk of developing 
IVDD compared with patients with the TT genotype. Similar to 
the -1306C/T SNP, the T allele was associated with disrupting a 
Sp1-binding site (CCACC box) and reducing transcription, while 
the C allele was considered the wild-type and was associated with 
increased transcription (39). These studies reveal that multiple 
nearby Sp1-binding sites whose polymorphisms are connected 
to genetic risk of IVDD exist (38, 39).
MMP-9 is also a gelatinase with variable expression that 
has been linked to IVDD. A 2009 study by Sun et  al. revealed 
a -1562C/T polymorphism that affected the protein expression 
of MMP-9 (11). Patients with the CT/TT genotypes were at 
a 2.14-fold increased risk of developing IVDD compared with 
patients with the CC genotype. The T allele is associated with 
increased MMP-9 expression, and thus an imbalance between 
MMPs and tissue inhibitors of metalloproteinases, leading to 
excessive degradation of the ECM (11).
MMP-3 is one of the three MMPs that are categorized as 
stromelysins (59). One of the main functions of stromelysins is 
to degrade proteoglycans, laminas, and other components of the 
IVD ECM as well as indirectly degrade the disc through activat-
ing other MMPs (40). Expression of MMP-3 has also been shown 
to rise in response to inflammation (51).
The most commonly studied SNP of MMP3 is the 5A variant 
allele in the promoter region of the gene. A 2001 study by Takahashi 
et al. revealed that elderly patients who had the 5A/5A or 5A/6A 
genotype were at an increased risk of IVDD (40). However, the 
study did not find this association in younger patients. Yuan et al. 
investigated the same 5A polymorphism and found that patients 
who carried the shorter 5A allele were at a 1.96-fold increased 
risk of developing IVDD (12). More recently, Zawilla et al. found 
that the 5A allele was associated with a 2.5-fold greater risk of 
developing IVDD (51). The study also found a link between the 
5A allele and increased severity of degradation. An abundance of 
evidence suggests that the shorter 5A polymorphism of MMP3 is 
linked to an increased genetic risk of IVDD (51).
MMP-14 is a membrane-anchored MMP that is found at 
the cell surface and is involved in degrading small fragments 
of collagen and activating MMP2 (41, 59). Researchers have 
hypothesized that overexpression of MMP-14 leads to overall 
disc degradation mainly through the activation of MMP2 (41). 
In a 2015 study by Zhang, the -378T/C SNP in MMP14 was a 
genetic risk factor associated with IVDD (41). Patients with the 
TT genotype had a 1.59-fold increased risk of IVDD compared 
with patients with the CC genotype.
Considering all the various SNPs associated with MMPs and 
their influence on patients’ risk of developing IVDD, protein 
expression levels are a delicate and important aspect of ECM 
maintenance of IVDs. It is possible that genetic manipulation 
of MMPs is a significant factor in the etiology behind IVDD. 
Furthermore, MMPs are strong candidates for therapeutic 
options for mitigating or reversing IVD degradation.
A Disintegrin and Metalloproteinase with 
Thrombospondin Motif
A disintegrin and metalloproteinase with thrombospondin motif 
are enzymes that play a central role in disc degeneration via aggre-
can turnover (42). In particular, ADAMTS-4 and ADAMTS-5 are 
found at the site of disc degeneration. Various genetic polymor-
phisms in the ADAMTS family of genes are linked to the risk of 
IVDD. Liu et al. were the first to investigate a polymorphism in 
ADAMTS4 (42). They found that SNP rs4233367, an 1877C/T 
substitution, was associated with a reduced risk of IVDD. Patients 
with the TT genotype were at a 0.21-fold reduced risk of devel-
oping IVDD compared with those with the CC genotype. This 
strong connection suggests that ADAMTS4 plays an important 
part in proteoglycan degradation within the IVD. Rajasekaran 
et  al. investigated SNP rs162509 in ADAMTS5 and found that 
the risk allele was associated with a 1.281-fold increased risk of 
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developing IVDD (34). Although this relationship is small, it 
supports the notion that ADAMTS proteins are essential for the 
maintenance of healthy, hydrated discs.
Aggrecan
Aggrecan is the most plentiful proteoglycan found within the 
IVD, and its primary function is to retain water. The core protein 
of aggrecan contains a large number of chondroitin sulfate and 
keratin sulfate chains that facilitate its ability to create an osmotic 
gradient. Furthermore, aggrecan binds to negatively charged gly-
cosaminoglycans to increase the hydrostatic pressure of the NP 
(5, 7). One of the most investigated polymorphisms of aggrecan is 
the variable nucleotide tandem repeat (VNTR) in the chondroitin 
sulfate-1 encoding domain of the aggrecan gene (ACAN) (45). 
The chondroitin sulfate encoding allele has VNTRs ranging from 
13 to 33 nucleotides, with the most common number being 26, 
27, or 28 repeats. As aggrecan water-retention abilities are heav-
ily reliant on the number and size of chondroitin sulfate chains, 
it makes sense that a reduced number of repeats would impair 
the ability of aggrecan to retain water (24, 43–46). One of the 
earliest studies published on this topic was in 1999 by Kawaguchi 
et al. (43). The study found patients with 18 or 21 repeats in the 
chondroitin sulfate encoding domain were at an increased risk 
of multilevel disc degeneration as well as more severe forms of 
degeneration when compared with patients with longer alleles. A 
2010 study by Eser et al. supported these results (24). They found 
that patients with short alleles, consisting of VNTRs of A13 to 
A26, were at an increased risk of severe disc degeneration com-
pared with those with longer VNTRs in their alleles. The study 
also found that patients with short, A13 to A26, or normal, A27, 
were at an increased risk of multilevel disc degeneration. These 
findings were further supported by a 2012 study by Xu et al. who 
found that patients with less than 23 VNTRs were at a 1.95-fold 
increased risk of IVDD compared with those with more than 23 
repeats (44). The study also found that patients with less than 25 
repeats were at a 1.85-fold increased risk of IVDD compared with 
those with more than 25 repeats. This study helped establish the 
dose-dependent nature of the VNTRs of the aggrecan gene. The 
risk associated with VNTRs seems to follow a continuous scale, 
as opposed to a Boolean, or “cut-off ” pattern (44). A 2013 meta-
analysis by Gu et al. revealed that patients with shorter alleles, 
A13 to A25, were at a 1.54-fold increased risk of IVDD compared 
with those with either normal, A26 to A27, or longer alleles, A28 
to A32. This relationship was found to be even stronger in patients 
of Asian descent, who were at a 1.65-fold increased risk of IVDD 
(45). This study helped solidify the notion that shorter VNTRs are 
not only associated with increased risk of IVDD but also suggest 
that the magnitude of the effect may be associated with race.
In 2007, Solovieva et al. investigated the VNTRs for the aggre-
can gene in 132 middle-aged Finnish men (46). Their analysis 
found that the A26 allele was associated with an increased risk of 
the patient’s NP to be dark on an MRI scan, which is an indication 
of IVDD. The study also found that patients with A26/A26 geno-
type were at a 2.77-fold increased risk of a dark NP compared with 
patients who had longer or shorter VNTRs. This study is unique 
and did not follow the same trends as the previously mentioned 
studies. In previous studies, A26 was either considered within 
normal/typical range or even long (24, 43–45). This 2007 study 
helped support the notion that the effects of VNTRs may also be 
influenced by the race or ethnicity of the patient.
Various other genes that affect the aggrecan water-retention 
abilities or aggrecan expression have also been investigated. 
Carbohydrate sulfotransferase 3 (CHST-3) is an enzyme that is 
involved in sulfation of the aggrecan side-chains and is coded by 
CHST3. This function makes CHST-3 an important and indirect 
contributor to disc hydration. Song et  al. identified the SNP 
rs4148941 that produced the risk allele A (47). They found that 
the allele A variant of CHST3 had improved binding with micro 
RNA sequence miR-513a-5p. Their statistical analysis showed 
that patients with the AA or AC genotypes were at a 1.48-fold 
increased risk of developing IVDD. Further analysis revealed that 
the A allele was associated with reduced expression of the CHST3 
messenger RNA within the IVDs, suggesting reduced expression 
of CHST-3 protein (47). Overall, the study established the SNP of 
CHST3 as a genetic risk factor for IVDD.
vitamin D Receptor
The VDR is a nuclear receptor for a vitamin D metabolite, 1a,25-
dihydroxyvitamin D3 (Figure 3). Previous studies have shown that 
VDR polymorphisms are associated with various bone disorders 
including osteoarthritis, osteoporosis, and cardiovascular disease 
(7, 44). VDR function in IVDs is hypothesized to be through an 
indirect pathway for chondrocyte proliferation and the effect of 
chondrocytes on proteoglycans (12). Over the past two decades, 
various polymorphisms affecting the expression and function of 
VDRs in IVDD have been identified. These SNPs include FokI 
(rs2228570), TaqI (rs731236), and ApaI (rs7975232) (12, 20, 24, 
44, 48, 49, 51, 61, 62).
The FokI polymorphism of VDR is a C to T substitution found 
in exon 2 (49). This SNP leads to altered protein size, and sub-
sequently, altered function. Research has shown that the shorter 
polypeptide of VDR is associated with the wild-type C variant. 
The F allele has a higher affinity for transcription factor II B. The 
wild-type alleles lead to normal functioning VDR, while the T 
substitution (risk allele f) is associated with reduced function 
(62). A 1998 study by Videman et al. of Finnish twins found that 
the ff genotype was associated with 9.3% reduced signal intensity 
within the T6–S1 region on an MRI compared with the FF geno-
type (48). They also found that the Ff genotype was associated 
with 4.3% reduced signal intensity within the same region. These 
results were supported by a 2010 study by Eser who found that 
the FF genotype was associated with milder grades of degrada-
tion (grades I and II), whereas the ff genotype was associated 
with more severe grades (grades III and IV) (24). The FokI SNP 
was not only associated with an increased severity of IVDD but 
also increased the risk of developing IVDD. Vieira et al. found 
that the T allele was associated with a 1.58-fold increased risk of 
developing IVDD compared with the C allele (49). These results 
were further supported by a recent 2016 study by Zhao et  al. 
They found that Hispanic patients with the ff or Ff genotype 
(TT or TC alleles) were at a 1.742-fold higher risk of developing 
IVDD, whereas Asian patients with similar genotypes had a 
1.293-fold increased risk (62). The data on the FokI SNP suggest 
that it is a genetic risk factor not only for IVDD but also for the 
FiGURe 3 | illustration outlining the vitamin D receptor (vDR) signaling pathway. VDR/retinoid X receptor (RXR) interaction with vitamin D response element 
(VDRE) stimulates gene transcription. Used with permission from Barrow Neurological Institute, Phoenix, AZ, USA.
11
Martirosyan et al. Genetics of Degenerated Discs
Frontiers in Surgery | www.frontiersin.org November 2016 | Volume 3 | Article 59
severity of IVDD. Furthermore, these data suggest that the FokI 
polymorphism manifests differently in patients based on race 
or ethnicity.
Another significant SNP of VDR that has been the target of 
the most investigation among VDR polymorphisms is the TaqI 
variant (44). Interestingly, TaqI is a silent mutation in exon 9 of 
the VDR gene, yet it has a profound effect on a patient’s genetic 
risk of developing IVDD (50). One of the earliest studies of the 
TaqI polymorphism was the 1998 study by Videman et al. (48). 
They found that the patients with the tt genotype displayed 12.6% 
reduced signal intensities in the T6–12 range on MRI compared 
with patients with the TT genotype. These findings were sup-
ported by a 2002 study by Kawaguchi et al. who investigated the 
incidence of the TaqI SNP in Japanese young adults (50). The study 
found that patients with the Tt genotype were at an increased 
risk of multilevel IVDD and more severe forms of degeneration. 
The study was unable to establish the same connection for the 
tt genotype because none of the subjects had the tt genotype. 
In 2010, Eser et  al. found that patients with the TT genotype 
displayed significantly milder forms of IVDD than patients with 
the tt genotype (24). A study in 2015 by Toktas et al. supported 
the association of the TaqI SNP with increased severity of disc 
degeneration. They found that patients with the homozygous tt 
genotype had an average Pfirrmann score of 18.45, which was 
significantly lower than in those with wild-type genotypes (aver-
age score, 22.15) (20). The findings from these studies suggest 
that the TaqI SNP of VDR is associated with both increased risk 
of developing IVDD and severity of IVDD.
Another common polymorphism of VDR that has received 
much attention is the ApaI SNP. The ApaI SNP maps to intron 8 
of VDR and is associated with increased risk of IVDD (50). Yuan 
et al. found that the risk allele of the ApaI SNP was associated 
with a 1.70-fold increased risk of developing IVDD (12). These 
findings are supported by a 2013 study by Zawilla et al. who found 
that the mutant T allele of VDR was associated with a 3.1-fold 
increased risk of developing IVDD (51). They also found that the 
mutant T allele was significantly associated with increased sever-
ity of IVDD. Although the ApaI polymorphism is associated with 
both severity and risk of developing IVDD, the exact mechanism 
and its impact on the VDR protein has not been thoroughly 
investigated (12, 50, 51). Despite this, ApaI is a well-established 
genetic risk factor of IVDD.
Apoptosis
Studies regarding the molecular mechanisms of IVDD have 
established that degenerated discs display much higher rates 
of apoptosis, programed cell death (3, 5). Although the exact 
cascade of molecules involved in apoptosis of IVD cells remains 
under investigation, there are a few significant genes whose poly-
morphisms have been associated with increased risk of IVDD. 
Among these are caspase-9 (CASP9), TNF-related apoptosis-
inducing ligand (TRAIL), and death receptor-4, DR4, also known 
as TRAIL receptor 1 (TRAILR1) (1, 10).
Caspase-9 is an important activator of the intrinsic pathway 
of apoptosis. Its expression levels within the IVD have been 
reported to increase during disc degeneration (1). The first 
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study to report on CASP9 polymorphisms and their relation-
ship to IVDD was a 2011 study by Guo et  al. (1). The study 
investigated two SNPs, rs4645978 (-1263A/G) and rs4645981 
(-712C/T). They analyzed data from 154 patients with IVDD 
and found that the mutant GG genotype was associated with a 
2.760-fold increase in the risk of IVDD compared with the AA 
genotype (1). Mu et  al. investigated the same polymorphism, 
-1263A/G, and found that the G allele was associated with a 
2.059-fold increase in the risk of developing lower back pain 
compared with the A allele (52). These studies suggest that 
SNPs affecting the expression and function of apoptosis factors 
may be another way in which genetic factors influence the 
progression of IVDD.
DR4 and DR5 are both receptors that bind to TRAIL 
and induce apoptosis within the target cell. Recent studies 
have shown that the TRAIL/DR4/DR5 system is important 
in mediating apoptosis within IVDs (10). Polymorphisms 
that influence the function and expression of either TRAIL 
or DR4 can significantly impact the rate of apoptosis occur-
ring within IVDs. Xu et  al. identified two polymorphisms of 
TRAIL within the 3′-untranslated region, such as 1525A/G and 
1595T/C, which are associated with IVDD (53). The mutant 
GG genotype at the 1525 locus and the mutant CC genotype 
of the 1595 locus were associated with increased risk of IVDD. 
The investigation found that both the GG1525 and CC1595 
genotypes were associated with reduced TRAIL expression 
within the cells as well as more severe forms of IVDD (grade 
IV). Although reduced TRAIL expression has already been 
established in IVDD, the underlying pathophysiology remains 
under investigation (53).
The TRAIL/DR4/DR5 system is also affected by polymor-
phisms in DR4. Tan et al. found that degenerating IVD cells had 
increased expression of DR4 (25). They investigated a Chinese 
Han population and found that SNP rs4871857 (626C/G) in exon 
4 of DR4 was associated with IVDD. Patients with the mutant 
G allele were at a 1.958-fold increased risk of developing IVDD. 
Furthermore, the GG and CG genotypes were associated with 
more severe grades of IVDD (25). The findings on TRAIL and 
DR4 revealed another aspect of IVDD that may be controlled by 
genetic factors.
Growth Factors
Growth differentiation factor 5 (GDF5) is part of the transform-
ing growth factor-β superfamily involved in bone, ligament, and 
soft tissue development (52, 54). Increased GDF5 expression is 
linked to increased collagen II and aggrecan production in human 
IVDs (63, 64). An investigation of polymorphisms in GDF5 
revealed that its variable expression and function are linked to 
osteoarthritis. Williams et al. investigated SNP rs143383 (a T to C 
substitution at position 104) located within the promoter region 
of the GDF5 gene. Their analysis showed that the T allele was 
associated with 1.72-fold increased risk of disc space narrowing 
and osteophyte production in women (54). These findings are 
supported by a 2013 study by Mu et al. who investigated the same 
SNP (52). They found that the T allele of GDF5 was associated 
with a 2.115-fold increased risk of lower back pain. Although 
the study revealed an association between the T allele and lower 
back pain, the findings still suggest the involvement of GDF5 
polymorphisms in IVDD.
Similar studies have investigated the influence of vascular 
endothelial growth factor (VEGF) gene polymorphisms and 
their link to IVDD (55). IVDs are some of the largest avascular 
structures within the human body. Consequently, they rely on 
small capillaries extending from the lumbar artery to help remove 
metabolic waste (5). One of the main features of a severely 
degenerated disc is neovascularization penetrating the AF, hence, 
the interest in VEGF, a key mediator of angiogenesis (55). Han 
et al. found that when a patient possessed multiple VEGF SNPs, 
there was a significant association with IVDD (55). For example, 
a patient with the genotype of -2578CA or AA, combined with 
-634CC genotype, was at a 21-fold increased risk of IVDD. With 
limited data, it is difficult to conclude with certainty that VEGF 
SNPs are associated with IVDD; however, Han et al. (55) have 
helped establish the preliminary data to warrant further investi-
gation into VEGF polymorphisms.
Ubiquitin-Mediated Degradation
E3 ubiquitin-protein ligase is a multiprotein complex that func-
tions in an ubiquitin–proteasome pathway, marking proteins 
for degradation. A key protein in this complex named Parkin is 
expressed in various organs and skeletal muscles. Parkin is coded 
by PARK2, which was recently associated with IVDD (8, 56). In a 
2013 study of 4600 Northern Europeans, Williams et al. reported 
that the rs926849 SNP is a T to C substitution found within an 
intron of PARK2 (56). Their statistical analysis revealed that the 
C allele was significantly associated with reduced risk of IVDD, 
suggesting that the C allele was protective. The underlying mech-
anism of how the C allele influences the expression of PARK2 
and the subsequent pathology remains under investigation (56). 
Nonetheless, this study adds another component to the etiology 
of IVDD as well as highlighting the complexity and continued 
discoveries associated with IVDD.
Cyclooxygenase
Cyclooxygenase 2 is an essential enzyme that is involved in the 
production of various prostaglandins and thromboxanes. The 
cyclooxygenase 2 gene COX2 and its products participate in 
multiple pathways including inflammation and pain (8, 34, 65). 
In 2015, Rajasekaran et al. identified two SNPs, such as rs5277 
and rs5275, in COX2 that are significantly associated with severe 
IVDD (34).
Catechol-O-Methyltransferase
Catechol-O-methyltransferase is an enzyme that is involved in 
the degradation and processing of catechol neurotransmitters 
such as dopamine. Previous clinical studies showed a relationship 
between certain polymorphisms in the catechol-O-methyltrans-
ferase (COMT) gene and pain. The IVDD researchers believed 
that variable catechol-O-methyltransferase expression led to 
increased pain in IVDD. Gruber et  al. identified four COMT 
SNPs, such as rs4633, rs165656, rs2095019, and rs4708592, sig-
nificantly associated with IVDD (57). Their findings supported 
results that were previously published regarding the association 
of rs4633 and IVDD. Although rs165656 has previously been 
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associated with mental retardation, Gruber et al. were the first to 
show its significant association with IVDD (57). The rs2095019 
and rs4708592 polymorphs are novel SNPs that have not been 
reported previously (57). The study is a strong indicator of the 
complexity of the acute and chronic changes that occur with 
IVDD as well as highlighting the ongoing research that has 
revealed new aspects of its etiology.
Personalized Medicine
The ultimate goal in reviewing the medical literature about the 
genetic polymorphisms associated with IVDD is to provide 
patients with personalized and targeted therapeutics. When a 
patient enters a clinic with lower back pain and degenerative disc 
disease is suspected, an MRI can provide a conclusive diagnosis. 
To provide targeted treatment for the specific patient, the physi-
cian must understand the patient’s unique molecular profile. 
Through gene sequencing and screening for SNPs, physicians 
can obtain a better understanding of the imbalances that led to 
the patient’s disc degeneration. Some patients may primarily have 
imbalances with ECM degrading enzymes, whereas others may 
have overexpression of proapoptotic factors. With this informa-
tion, unique to each patient, specific therapies can be selected to 
provide the best long-term outcome.
CONCLUSiON
Despite continued research, the etiology and pathophysiology 
underlying IVDD remain poorly understood (34). Nonetheless, 
a significant shift in the understanding of IVDD has occurred 
over the past two decades, and we now understand that roughly 
75% of the etiology behind IVDD is genetic (2, 6). One of the 
crucial techniques that have helped researchers to realize this 
understanding is the advent of large-scale DNA arrays and com-
putational analysis software to analyze polymorphisms quickly 
(34). These techniques have helped bring to light new proteins 
and associations within systems that were previously thought 
not to be linked to IVDD. With a better understanding of the 
pathophysiology of IVDD and improved technology for scanning 
entire genomes for SNPs than in the past, we expect to produce 
innovative, new therapeutic approaches.
Two important aspects of genetic polymorphisms that have 
come to light are variations in race and ethnicity. Some polymor-
phisms tend to have stronger, or even no effect, on certain races. 
For example, Hispanics with the FokI SNP of VDR were at a much 
higher risk of IVDD than their Asian counterparts. Furthermore, 
the same meta-analysis found that the FokI SNP was not associ-
ated with IVDD in people of Caucasian decent (62). These racial 
variations add a new aspect and complexity to the understanding 
of the genetic factors underlying IVDD.
With more than 20 unique polymorphisms associated with 
IVDD, the molecular changes in the associated proteins or 
pathology of the disc are not yet fully understood. In the coming 
years, research targeted toward fully understanding the protein 
changes due to the already identified SNPs is crucial. If we can 
fully understand the molecular changes involved in IVDD then 
creating targeted therapeutics based on genetic profiling becomes 
a possibility.
With improved understanding of the genetic variants associ-
ated with IVDD, and rapid genomic analysis available through 
next-generation genotype sequencing, the possibility of provid-
ing effective personalized medicine can become a reality (14, 
15). This comprehensive literature review regarding the genetic 
variants associated with IVDD not only affords a better under-
standing of the molecular mechanisms behind IVDD but also 
allows physicians the possibility of providing targeted treatments. 
For instance, if an IVDD patient were identified to have genetic 
variants resulting in the overexpression of apoptotic factors, 
physicians would be able to refine their therapy and target the 
specific underlying IVDD-causing mechanism unique to that 
patient. Furthermore, genomic screening for the known variants 
associated with IVDD can help predict disease progression and 
severity. This knowledge can help provide more effective treat-
ments personalized to the unique phenotypic presentation of 
the patient. Considering the majority of the etiology underlying 
IVDD is genetic, it is essential that researchers and clinicians have 
a keen understanding of this underlying etiology to optimize 
treatment (2). Consequently, DNA screening for the genetic vari-
ants explaining the pathophysiology of the patient’s IVDD should 
be the standard of care.
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